Kano Therapeutics

Biotechnology · Cambridge, MA · Founded 2021 · Privately Held (backing)

Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. Kano Therapeutics is based in Cambridge, MA and was founded in 2021. It was valued at $15 million at its seed round in Aug 2024, the last priced event on record. It has raised $7.4 million across 2 recorded rounds; the latest was a $5 million seed round in Aug 2024.

PMV mark · valuation
$15.0M
Oct 2026
Priced at
its seed round
Aug 2024
Total raised
$7.4M
Last round
Seed Round
Aug 2024
What is Kano Therapeutics worth?
$15.0MPrivateMarketView mark · Oct 2026

Valued at $15.0M at its seed round, Aug 2024. Nothing has traded since.

Free account
More of Kano Therapeutics with a free account
  • ·The complete investor list: 12 names
  • ·Watch Kano Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Kano Therapeutics funding history

2 rounds
DateRoundRaisedPost-money
Aug 2024Seed Round$5.0M▮
May 2022Seed Round$2.1M▮
Unlock post-money valuations

Membership and data by Private Market View

Kano Therapeutics valuation

Kano Therapeutics was valued at $15 million at its seed round in Aug 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Kano Therapeutics raised?

Kano Therapeutics has raised $7.4 million across 2 recorded rounds since 2022. The largest was a $5 million seed round in Aug 2024.

Kano Therapeutics has filed 1 Form D with the SEC, most recently in May 2024 ($5 million sold to 4 investors).

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Azalea Therapeutics ($153 million), KaloCyte ($24.7 million) and Industrial Microbes ($24 million).

How Kano Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Kano Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Kano Therapeutics

What is Kano Therapeutics worth?
Kano Therapeutics is valued at $15.0M as of Oct 2026. Valued at $15.0M at its seed round, Aug 2024. Nothing has traded since.
How much has Kano Therapeutics raised?
Kano Therapeutics has raised $7.4M in total funding across 2 recorded rounds.
When did Kano Therapeutics last raise?
Kano Therapeutics last raised in Aug 2024 (Seed Round), raising $5.0M.